To access this element change to forms mode OFF
Grant Award View - GA22380
The development of Tigilanol Tiglate as a neo-adjuvant in...
GA ID:
GA22380
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
16-Jul-2018
Publish Date:
2-Oct-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2021
Value (AUD):
$657,521.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Development Grants
Grant Activity:
The development of Tigilanol Tiglate as a neo-adjuvant in immuno-oncology
Purpose:
Despite the progress made with new immunotherapies for treating metastatic cancer, lack of response in most patients remains a challenge. Our work with Tigilanol Tiglate (currently in human clinical trials as a locally-delivered treatment for a range of solid tumours) has shown that this agent can stimulate immune cell activity in non-responsive cancers. This project will extend the use of this drug, alone or in combination with other therapies, as a new option in treating metastatic cancers.
GO ID:
GO Title:
Development Grants
Internal Reference ID:
GNT1158281
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
QIMR Berghofer Medical Research Institute
Recipient ABN:
31 411 813 344
Grant Recipient Location
Suburb:
Herston
Town/City:
Herston
Postcode:
4006
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
QLD
Postcode:
Country:
AUSTRALIA